Day Zero Diagnostics, a startup co-founded by Miriam Huntley, Ph.D. ’16 (applied math) was awarded $6.2 million from the Boston-based Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator.
The startup, which was incubated at the Pagliuca Harvard Life Lab, is developing a sequencing-based and machine learning-powered diagnostic system that identifies, within hours, both the species and the antibiotic resistance profile of a bacterial pathogen. The startup will use the funding to help develop three current projects.
Huntley is the co-founder and CTO of Day Zero Diagnostics, which was launched in 2016.
Press Contact
Adam Zewe | 617-496-5878 | azewe@seas.harvard.edu